Objective: Few studies have described mortality and clinical outcomes after myocardial infarction (MI) in the HIV-positive population. This study evaluated changes in short-term mortality after MI in HIV-positive individuals in the D:A:D Study, and investigated possible reasons for any changes seen.
Introduction
The mortality rate after a first myocardial infarction (MI) has declined in individuals of all ages in the general population over the past 25 years [1, 2] . This improvement is mainly attributable to better management of cardiovascular disease (CVD) risk factors and the increased use of recommended medical therapies and invasive cardiovascular procedures (ICPs) [1, 2] . It is well documented that HIV-positive persons have a higher risk of CVD; multiple factors, not all of which are fully explained, may contribute to development of atherosclerosis in this population. The prevalence of many traditional CVD risk factors (e.g. smoking, dyslipidemia) is higher in HIVpositive persons than in the general population [3, 4] . Although some studies have reported an improvement over the years [5] , earlier findings from the D:A:D Study demonstrated that the CVD risk profile of individuals living with human immunodeficiency virus (HIV) in the cohort generally worsened from 1999 to 2006 [6] . In addition, exposure to some antiretroviral drugs has been shown to be associated with an increased risk of MI [7, 8, 9, 10, 11, 12] . Furthermore, the increased CVD risk noted in HIV-positive individuals may also be related to HIV-related chronic inflammation and immunosuppression [10, 8, 13, 14, 15, 16] . Whilst incidence rates of MI in the HIV-positive population are higher than in the HIVnegative population [17, 18, 13] , there has been a decrease in the rate over time in the D:A:D Study, likely as a result of a more aggressive targeted approach to the management of CVD risk factors [6] . Recent studies have also reported a decreasing trend to the excess MI risk in HIVpositive people compared with the general population in later years [19, 20] .
Examples of independent predictors of increased mortality after MI in the general population include older age, male sex, in-hospital cardiac complications and no ICP after MIs [21] . Previous findings have shown that HIV-positive individuals admitted for acute coronary syndromes faced a substantial short-term risk of death and an increased risk of coronary revascularization, recurrent MI [22] and all-cause mortality one year after MI [23] . However, few studies have described mortality and clinical outcomes after MI in the HIV-positive population and changes in such outcomes over time. The primary objective of this study was to investigate changes over time in short-term mortality after MI in HIV-positive participants in the D:A:D Study, and possible explanations for any changes seen.
Material and methods
The D:A:D (Data on Adverse events of antiretroviral Drugs) Study is a large, prospective observational cohort study which follows >49 000 HIV-positive persons from 11 collaborating cohorts in Europe, USA and Australia; to date, these persons have contributed >350 000 personyears of follow-up (PYRS). The primary aim is to investigate associations between the use of antiretroviral drugs and risk of CVD [7] . The data include information on socio-demographic factors, acquired immunodeficiency syndrome (AIDS) events, CD4 þ cell count, HIV viral load, other laboratory results, antiretroviralregimen/treatment history and CVD risk factors/treatments. Data are reported to the D:A:D coordinating centre as anonymous, computerized case report files and then merged into a standardized central dataset. All cases of MI are validated centrally using criteria from the WHO MONICA Study [24] and classified using a Dundee score [24] as definite, possible or unclassifiable and further distinguished into nonfatal and fatal events. In addition, ICPs [coronary artery bypass graft (CABG), carotid angioplasty (ANG) and carotid endarterectomy (END)] are reported. Information on causes of death is collected using a designated Coding of Causes of Death in HIV (CoDe) form (www.chip.dk/code) [25] . This analysis was conducted in accordance with the Declaration of Helsinki and approved by national ethical committee where necessary.
Statistical methods
All individuals experiencing an MI during prospective follow-up from study initiation in 1999 to February 1, 2014, were identified. Demographic, HIV/CVD-related characteristics and the use of CVD interventions [ICPs, receipt of antiplatelets, angiotensin-converting enzyme inhibitors (ACEIs), other antihypertensives (including beta-blockers) and lipid-lowering drugs (LLDs)] were described at the time of the MI and over the follow-up period. Mortality after MI was described using KaplanMeier methods, with follow-up on individuals who remained alive being right-censored 6 months after their last clinic visit or on 1st February 2014, whichever was earlier. Only the first MI that occurred over follow-up was considered for each individual (although some individuals had experienced their first ever MI prior to enrolment in the study).
Factors associated with overall mortality and mortality from the first month after MI onwards were identified using Cox proportional hazards regression models. Factors (measured at the time of MI) that were considered for inclusion in these models were: age, sex, mode of HIV acquisition, ethnicity, cohort, calendar year of MI, current/cumulative exposure to antiretroviral therapy (ART), prior AIDS diagnosis, CD4 þ cell count, viral load, smoking status, body mass index, family history of CVD, hypertension (SBP >140 mmHg and/or DBP >90 mmHg and/or on ACEIs or other antihypertensives [26] ), dyslipidaemia [total cholesterol (TC) !6.2 mmol/l or hyperdensity lipoprotein cholesterol (HDL-C) 0.9 mmol/l or TC:HDL-C ratio !6.5 or receipt of LLDs [26] ], prior diabetes, prior stroke (both centrally validated), prior MI and Framingham risk score. Factors that were associated with mortality in univariable analyses (P < 0.1) were considered for inclusion in the multivariable model with a stepwise selection procedure used to identify the factors that would be retained in the model. The resulting model was then further adjusted for interventions received in the first month after MI.
Factors associated with short-term mortality (deaths occurring within the first 31 days after MI) were identified using unadjusted/adjusted logistic regression models with potential confounders selected as described above. All models included calendar year as this was our exposure of interest; analyses were restricted to individuals with at least 1 month of follow-up (or those who had died within the first month) to avoid introducing bias due to variable follow-up times over this first month. Analyses were performed separately for CVD/non-CVD related deaths and stratified by calendar period.
Results
Characteristics of individuals at time of an MI One thousand and eight D:A:D participants experienced an MI over the period 1999-2014. The majority were men (90.8%), the median [interquartile range (IQR)] age at the time of MI was 51 (44, 58) years, and 55.9% were of white ethnicity. The most prevalent CVD risk factors seen were dyslipidemia (66.6%), current smoking (53.3%) and hypertension (42.5%); around one in three individuals with an MI were known to be receiving LLDs (35.5%) and one in four (26.4%) antihypertensives. At the time of MI, 90.4% of the individuals were on ART with only 2.7% being antiretroviral-naive (the remaining 6.9% had previously received ART). The median (IQR) 10-year predicted CVD risk (based on the Framingham score, available in 82.1% of those with an MI) was 14.1% (8.9%, 20.7%) ; 58.2% of the individuals with an available score had a moderate to high predicted risk of more than 10% (Table 1 ).
The number of MIs in each year is shown in Table 1 . The proportion of MIs in each year that was classified as definite MIs was stable (58.9% in 1999-2002 to 60.4% in 2011-2014) . There were some changes in the characteristics of individuals that experienced an MI over the same period; the median age increased from 48 to 54 years, the proportion of current smokers increased from 49.5 to 54.6%, and there were increases in the proportions of individuals who had dyslipidemia, hypertension and a moderate/high Framingham risk score. In more recent years, a higher proportion of individuals were on ART, had a suppressed viral load and a higher CD4 þ cell count (Table 1) . Of the deaths that occurred, 145 (42.8% of deaths, 14.4% of all individuals) were on the same day as the MI, 37 (10.7% of deaths, 3.7% of all individuals) were within the first month after the MI, and 157 (46.3% of deaths, 15.6% of all individuals) were more than 31 days after MI. The proportion of deaths that was due to CVD varied according to the timing of the death relative to the MI: 129 (89%) and 33 (87.1%) of deaths that occurred on the same day as the MI or within the first month after MI were due to CVD respectively, whereas only 59 (37.6%) of deaths that occurred more than 31 days after MI were due to CVD (Fig. 2a) . In total, 182 deaths occurred in the first month after MI yielding an overall short-term mortality rate of 18.1%; this rate dropped from 26.6% in 1999-2002 to 8.4% in 2011-2014 . The overall proportion of individuals dying from any CVD dropped from 72.6% in 1999-2002 to 40.9% in 2011-2014 , whereas the proportion of individuals dying from causes other than CVD following their MI increased over the same period; major contributing causes being HIV/ AIDS, non-AIDS cancers, bacterial infections, lung disease and unknown causes (Fig. 2b ).
Factors associated with overall mortality following MI In unadjusted proportional hazards regression models, factors associated with increased mortality were: older age; injection drug use (IDU) mode of HIV acquisition; black African ethnicity; prior AIDS; higher viral load; diabetes; prior MI; and prior stroke. Higher CD4 þ cell count, later calendar year of MI and family history of CVD were all associated with decreased mortality (data not shown). In a multivariable model, all these factors remained independently associated with mortality except black African ethnicity, prior AIDS and higher viral load.
In order to investigate the potential impact of interventions received in the first month post-MI, the analysis was repeated after excluding individuals who did not survive or remain under follow-up beyond the first month. Factors remaining independently associated with mortality in this multivariable model were: older age; prior AIDS; higher viral load; previous MI; diabetes; and later calendar year (Table 2) . Additional adjustment for the interventions received in the first month had only minor effects on the associations between these factors and mortality, although it led to an attenuation of the calendar year association from hazard rate 0.95 [95% confidence interval (CI) 0.89, 1.00] per later year to 0.98 (95% CI 0.92, 1.04) per later year (Table 2 ). Of the interventions themselves, only the ICPs demonstrated a strong association with mortality in this model.
Factors associated with short-term mortality following MI
In unadjusted logistic regression models, the factors associated with an increased risk of short-term mortality were: IDU mode of HIV acquisition; black African ethnicity; prior AIDS; higher viral load and prior stroke. A family history of CVD, higher CD4 þ cell count and later calendar year were associated with decreased risk of short-term mortality (data not shown). In a multivariable model excluding interventions during the first month after MI, IDU mode of HIV acquisition, higher CD4 þ cell count, family history of CVD and prior stroke continued to be associated with short-term mortality, and again there was a strong calendar year effect (Table 3) . When including interventions received in the first month following MI, ICPs, LLDs and antiplatelets were significantly associated with decreased risk of short-term mortality, and this led to attenuations of the associations with prior stroke [from odds ratio (OR) 3.24 (95% CI 1.61, 6.53 (Table 3) .
Discussion
We observed an improvement in survival after MI in the D:A:D cohort over the last 15 years. Those who experienced an MI continued to be individuals with a high CVD risk profile, although their HIV-related health indicators improved. There was an increase in the use of interventions at the time of, and shortly after an MI, and we observed a reduction in the short-term mortality rate following MI. Predictors of decreased short-term mortality were higher CD4 þ cell count, family history of CVD, later year of MI and the receipt of antiplatelets, LLDs and ICPs. When adjusting for CVD interventions in the first month after MI, the calendar year effect on short term-mortality was attenuated, arguing that the observed change is mainly driven by the increased use of interventions in recent years.
Within the D:A:D Study, we have seen a gradual reduction in the risk of MI over time in line with findings from the general population [27] , and in the present study, we observed some changes in the characteristics of individuals experiencing an MI. As previously documented [28] , the key demographic characteristics in individuals at the time of MI were male sex and older age, and other CVD risk factors were dominated by [6, 15, 29, 30, 31] . The proportion of individuals with an MI who were on ART with a suppressed viral load increased, as did the median CD4 þ cell count. This improvement in HIV-related health indices amongst participants in the study has probably contributed to the improved survival seen over the study period. The use of improved antiretroviral drugs with fewer metabolic sideeffects in recent years may also partly explain the improved survival, although we did not specifically investigate this in our study.
The HIV-positive population has changed significantly over the last decade as HIV/AIDS-related morbidity and mortality rates have declined and other causes of death have become increasingly common [32, 33, 34] . The allcause mortality rate in the D:A:D Study population fell from 17.5/1000 PYRS in 1999/2000 to 9.1 /1000 PYRS in 2009-2011; the leading causes of death being AIDS-and HIV-related causes, non-AIDS defining cancers, liver disease and CVD [32] . The crude CVD incidence mortality rate fell from 1.8/1000 PYRS to 0.9 /1000 PYRS from 1999 to 2011 [32] . In our analysis, nearly 90% of individuals who died within the first month after MI died of CVD-related causes. Although the short-term mortality rates after MI dropped, our findings emphasize the importance of continued Short-term mortality after myocardial infarction Hatleberg et al. 1589 Table 2 . Factors associated with mortality following MI, conditioned on the fact that patient survives for at least one month -multivariable model a .
Factor Excluding interventions in first month
Including interventions in first month improvement of the management of CVD in HIVpositive individuals. The magnitude of the reduction in short-term mortality after MI over time in this study (26.6 to 8.4% ) is similar to the reductions seen in the general population over the last 15-20 years, although mortality is still higher in our study population compared with equally young HIV-negative individuals (<65 years)
[1].
The clear improvements in survival outcomes in our study, particularly short-term mortality in the month following MI, appeared to be largely driven by improved clinical management. The use of ICPs increased by 35% from 1999-2002 to 2011-2014; where ICPs were used, angioplasties in particular tended to be undertaken on the same day as the MI. In some studies, HIV-positive individuals have previously been found to have a higher rate of recurrent MIs and to more frequently undergo urgent angioplasties [18, 28, 35, 36, 37] . The proportion of recurrent MIs in the study was 11.6%; which is higher compared with previous findings from the general population (8.9% in 2010) [38] . We were unable to systematically evaluate the type of MI and degree of vessel disease, but the relatively young median age of the study participants at the time of MI may indicate that a higher proportion may have had a ST-elevated myocardial infarction (STEMI), as an inverse relationship has been demonstrated in men in the general population between age and the likelihood of the MI being a STEMI [39] . A STEMI often requires urgent invasive treatment, possibly partly explaining the increased use of ICPs seen, and the latter may also be explained by the improvement in HIV-related characteristics, increasing the eligibility of individuals to undergo ICPs than was the case in earlier years.
We reported an increasing trend in the use of certain drugs following MI over time; LLDs and antiplatelets were the drugs most frequently started in those not already on these medications, arguing that secondary medical prophylaxis of CVD seem to be somewhat improving. The effectiveness and quality of CVD drugs may have also improved in more recent years, possibly contributing to improved survival.
In our study, we found that the calendar year effect on decreased short-term mortality seemed to be mediated through the increased use of CVD interventions in recent years, as its effect was attenuated after adjusting for interventions received in the first month after MI. Adjustment for interventions did not influence the decreased short-term mortality risk associated with a higher CD4 þ cell count. Similarly, adjustment for interventions received in the first month after MI also resulted in an attenuation of the calendar effect on longterm mortality, again suggesting that this effect was mediated through the use of interventions. Adjusting for interventions in the first month following MI did, however, not influence the predictors of increased longterm mortality, whereas the associations between stroke, family history of CVD and IDU mode of HIVacquisition and short-term mortality were weakened, suggesting also these associations to be partly influenced by the use of interventions.
One study previously demonstrated that HIV status influences long-term risk for adverse outcomes after MI by being an independent predictor for long-term risk of heart failure [40] . In our study, we were unable to assess the impact of HIV per se, but found that survival substantially improved in line with improvements in the CD4 þ cell count, which was an independent predictor for decreased short-term mortality. The current longerterm outcomes after MI need to be further explored in our study population.
Although we demonstrated that an increased number of HIV-positive individuals now receive invasive and medical interventions after MI, there is still a proportion of individuals surviving their MIs who do not appear to receive these interventions. One possible explanation is under-or delayed ascertainment of such interventions. However, findings from our annual monitoring process suggest that the number of missed clinical events in the D:A:D Study is very low. Complicating co-morbidities influencing the eligibility of a person to undergo ICPs, the type of MI, and differences in clinical practices at different medical centres may also play a role. Further, the use of drug interventions in those with HIV is often challenging given the possibility of drug-drug interactions with antiretroviral drugs [6, 41] , which may limit CVD treatment options. Finally, previous findings have reported that there is an inverse relationship between in-hospital mortality after MI and the number of CVD risk factors present at the time of MI [42] , indicating that low-risk individuals may therefore have other, as yet unidentified, factors which may contribute to progressive disease [42] . Some limitations to our study need to be acknowledged. The use of nonmedical interventions (e.g. dietary advice, advice on smoking cessation or exercise) is not captured systematically in the D:A:D Study, and may have contributed to improved survival. Further, it is complicated to evaluate the effect of relatively infrequent interventions, such as the use of ICPs, in an observational cohort as analyses of these interventions are likely to be affected by time-varying confounding and standard analytical methods are likely to give biased estimates. Finally, we did not evaluate the status of interventions at time of any recurrent MI although these may also have changed over time.
Conclusion
In this study, we demonstrated improvements in shortterm survival after MI in HIV-positive individuals, which appeared to be largely driven by increased use of drug interventions and ICPs. However, some individuals are still not receiving these interventions despite a high CVD risk profile. Our findings suggest that preventive measures need to be further explored, with targeted focusing on modifiable risk factors including smoking cessation, control of hypertension, dyslipidemia and diabetes as well as appropriate choice of antiretroviral drugs. 
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